Klingman & Associates LLC Grows Stake in Novo Nordisk A/S (NYSE:NVO)

Klingman & Associates LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 15.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,905 shares of the company’s stock after buying an additional 398 shares during the period. Klingman & Associates LLC’s holdings in Novo Nordisk A/S were worth $250,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of NVO. OLD National Bancorp IN lifted its position in Novo Nordisk A/S by 30.5% during the third quarter. OLD National Bancorp IN now owns 4,399 shares of the company’s stock valued at $524,000 after purchasing an additional 1,027 shares in the last quarter. Ledyard National Bank lifted its position in Novo Nordisk A/S by 6.2% during the third quarter. Ledyard National Bank now owns 4,285 shares of the company’s stock valued at $510,000 after purchasing an additional 250 shares in the last quarter. Waldron Private Wealth LLC lifted its position in Novo Nordisk A/S by 44.8% during the third quarter. Waldron Private Wealth LLC now owns 4,141 shares of the company’s stock valued at $493,000 after purchasing an additional 1,282 shares in the last quarter. Stanley Laman Group Ltd. purchased a new position in Novo Nordisk A/S during the third quarter valued at $282,000. Finally, Weaver Capital Management LLC lifted its position in Novo Nordisk A/S by 15.3% during the third quarter. Weaver Capital Management LLC now owns 2,298 shares of the company’s stock valued at $274,000 after purchasing an additional 305 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 1.3 %

Shares of NVO stock opened at $83.38 on Thursday. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock’s 50-day moving average price is $86.89 and its 200-day moving average price is $108.66. The stock has a market capitalization of $374.18 billion, a price-to-earnings ratio of 25.34, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Analyst Ratings Changes

NVO has been the topic of several analyst reports. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.